Weight-Loss surgery may change how blood pressure meds work

NCT ID NCT03476603

Recruiting now Knowledge-focused Sponsor: Norwegian University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates how gastric bypass or sleeve gastrectomy alters the absorption of irbesartan, a common blood pressure medication. Researchers will measure drug levels in the blood of 12 people with morbid obesity before and after surgery. The goal is to understand whether these procedures change how the body processes the drug, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Irbesartan
What this could lead to: If successful, this study could help doctors adjust blood pressure medication doses after bariatric surgery, improving treatment for patients.
What could go wrong: This is a very small, early-stage study (12 participants) that only measures drug levels in the blood, not health outcomes. Results may not apply to other medications or broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY, MORBID

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

St. Olavs University Hospital
RECRUITING

Trondheim, Norway

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.